Isle of Man vs Malta: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Isle of Man
0.0%
in 2024
Malta
0.0%
in 2024
Isle of Man rank
167th
Malta rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Isle of Man
- Malta
How they compare
Isle of Man currently reports 0.0% against 0.0% in Malta, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Malta ahead.
Isle of Man ranks 167th and Malta ranks 167th of 246 countries.
Isle of Man has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Isle of Man | Malta | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.0% | 0.1% | Isle of Man |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Isle of Man or Malta?
- Isle of Man, at 0.0% against 0.0% in Malta as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Isle of Man and Malta?
- 0.0%, with Isle of Man ahead.
- How many years of comparable data are there for Isle of Man and Malta?
- 10 years are reported by both, from 2015 to 2024.
- How do Isle of Man and Malta rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Isle of Man ranks 167th and Malta ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.